vs

Side-by-side financial comparison of Bank First Corp (BFC) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Bank First Corp is the larger business by last-quarter revenue ($44.9M vs $27.6M, roughly 1.6× Zymeworks Inc.). Bank First Corp runs the higher net margin — 45.8% vs -71.0%, a 116.8% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 12.1%). Bank First Corp produced more free cash flow last quarter ($51.0M vs $-31.8M).

First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

BFC vs ZYME — Head-to-Head

Bigger by revenue
BFC
BFC
1.6× larger
BFC
$44.9M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+60.5% gap
ZYME
72.6%
12.1%
BFC
Higher net margin
BFC
BFC
116.8% more per $
BFC
45.8%
-71.0%
ZYME
More free cash flow
BFC
BFC
$82.9M more FCF
BFC
$51.0M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BFC
BFC
ZYME
ZYME
Revenue
$44.9M
$27.6M
Net Profit
$18.4M
$-19.6M
Gross Margin
Operating Margin
51.0%
-80.1%
Net Margin
45.8%
-71.0%
Revenue YoY
12.1%
72.6%
Net Profit YoY
4.8%
34.3%
EPS (diluted)
$1.87
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFC
BFC
ZYME
ZYME
Q4 25
$44.9M
Q3 25
$44.2M
$27.6M
Q2 25
$41.6M
$48.7M
Q1 25
$43.1M
$27.1M
Q4 24
$40.1M
$31.0M
Q3 24
$40.8M
$16.0M
Q2 24
$38.9M
$19.2M
Q1 24
$37.7M
$10.0M
Net Profit
BFC
BFC
ZYME
ZYME
Q4 25
$18.4M
Q3 25
$18.0M
$-19.6M
Q2 25
$16.9M
$2.3M
Q1 25
$18.2M
$-22.6M
Q4 24
$17.5M
$-23.5M
Q3 24
$16.6M
$-29.9M
Q2 24
$16.1M
$-37.7M
Q1 24
$15.4M
$-31.7M
Operating Margin
BFC
BFC
ZYME
ZYME
Q4 25
51.0%
Q3 25
50.8%
-80.1%
Q2 25
49.7%
-1.4%
Q1 25
51.3%
-94.5%
Q4 24
54.4%
-71.6%
Q3 24
50.7%
-213.8%
Q2 24
51.0%
-222.9%
Q1 24
45.6%
-376.9%
Net Margin
BFC
BFC
ZYME
ZYME
Q4 25
45.8%
Q3 25
40.7%
-71.0%
Q2 25
40.5%
4.8%
Q1 25
42.3%
-83.5%
Q4 24
49.3%
-75.8%
Q3 24
40.6%
-186.6%
Q2 24
41.3%
-195.8%
Q1 24
40.8%
-315.6%
EPS (diluted)
BFC
BFC
ZYME
ZYME
Q4 25
$1.87
Q3 25
$1.83
$-0.26
Q2 25
$1.71
$0.03
Q1 25
$1.82
$-0.30
Q4 24
$1.75
$-0.32
Q3 24
$1.65
$-0.39
Q2 24
$1.59
$-0.49
Q1 24
$1.51
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFC
BFC
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$243.2M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$643.8M
$320.1M
Total Assets
$4.5B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFC
BFC
ZYME
ZYME
Q4 25
$243.2M
Q3 25
$126.2M
$64.8M
Q2 25
$120.3M
$98.3M
Q1 25
$300.9M
$76.2M
Q4 24
$261.3M
$66.1M
Q3 24
$204.4M
$122.4M
Q2 24
$99.0M
$71.0M
Q1 24
$83.4M
$114.8M
Stockholders' Equity
BFC
BFC
ZYME
ZYME
Q4 25
$643.8M
Q3 25
$628.1M
$320.1M
Q2 25
$612.3M
$334.5M
Q1 25
$648.4M
$325.0M
Q4 24
$639.7M
$338.8M
Q3 24
$628.9M
$367.0M
Q2 24
$614.6M
$406.2M
Q1 24
$609.3M
$438.0M
Total Assets
BFC
BFC
ZYME
ZYME
Q4 25
$4.5B
Q3 25
$4.4B
$397.3M
Q2 25
$4.4B
$408.4M
Q1 25
$4.5B
$425.5M
Q4 24
$4.5B
$463.1M
Q3 24
$4.3B
$487.2M
Q2 24
$4.1B
$515.6M
Q1 24
$4.1B
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFC
BFC
ZYME
ZYME
Operating Cash FlowLast quarter
$62.5M
$-31.4M
Free Cash FlowOCF − Capex
$51.0M
$-31.8M
FCF MarginFCF / Revenue
113.6%
-115.2%
Capex IntensityCapex / Revenue
25.5%
1.5%
Cash ConversionOCF / Net Profit
3.40×
TTM Free Cash FlowTrailing 4 quarters
$75.8M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFC
BFC
ZYME
ZYME
Q4 25
$62.5M
Q3 25
$15.5M
$-31.4M
Q2 25
$11.9M
$12.1M
Q1 25
$6.2M
$-3.4M
Q4 24
$65.8M
$-41.5M
Q3 24
$18.8M
$-5.9M
Q2 24
$14.9M
$-25.0M
Q1 24
$1.3M
$-37.7M
Free Cash Flow
BFC
BFC
ZYME
ZYME
Q4 25
$51.0M
Q3 25
$12.5M
$-31.8M
Q2 25
$8.2M
$11.6M
Q1 25
$4.0M
$-3.4M
Q4 24
$58.6M
$-41.8M
Q3 24
$16.9M
$-6.8M
Q2 24
$13.7M
$-25.6M
Q1 24
$551.0K
$-37.9M
FCF Margin
BFC
BFC
ZYME
ZYME
Q4 25
113.6%
Q3 25
28.2%
-115.2%
Q2 25
19.8%
23.7%
Q1 25
9.3%
-12.6%
Q4 24
146.3%
-134.8%
Q3 24
41.5%
-42.4%
Q2 24
35.3%
-133.0%
Q1 24
1.5%
-377.5%
Capex Intensity
BFC
BFC
ZYME
ZYME
Q4 25
25.5%
Q3 25
6.7%
1.5%
Q2 25
8.7%
1.1%
Q1 25
5.0%
0.1%
Q4 24
18.0%
1.0%
Q3 24
4.5%
5.6%
Q2 24
3.1%
3.1%
Q1 24
2.1%
1.8%
Cash Conversion
BFC
BFC
ZYME
ZYME
Q4 25
3.40×
Q3 25
0.86×
Q2 25
0.70×
5.21×
Q1 25
0.34×
Q4 24
3.75×
Q3 24
1.13×
Q2 24
0.93×
Q1 24
0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons